Hepatorenal syndrome (HRS) is a serious complication of advanced liver disease, such as cirrhosis, in which the kidneys become impaired and are unable to properly filter waste from the blood. This can lead to a buildup of toxins in the body, causing symptoms such as fluid retention, electrolyte imbalance, and decreased urine output. HRS is classified into two types: Type 1, which is rapidly progressive and typically occurs in patients with acute liver failure, and Type 2, which is slower in onset and occurs in patients with advanced chronic liver disease. Treatment for HRS typically involves managing the underlying liver disease, such as through medications, liver transplant, or dialysis to support kidney function. Prognosis for HRS can vary depending on the severity of the liver disease and the responsiveness to treatment.